Multivesicular liposome formulations of dexamethasone
Some embodiments of the present application are related to multivesicular liposome (MVL) formulations encapsulating dexamethasone or an ester or an ester salt thereof, for example, dexamethasone sodium phosphate (DSP) that may provide about 3-28 days extended release of dexamethasone. Processes of making and administering dexamethasone encapsulated multivesicular liposome formulations and their uses for treating pain or inflammation are also provided.
1. A composition of dexamethasone encapsulated multivesicular liposomes (MVLs), comprising:
dexamethasone, an ester or an ester salt thereof, and at least one pH modifying agent encapsulated in a plurality of internal aqueous chambers of the MVLs separated by lipid membranes, wherein the lipid membranes comprise at least one amphipathic lipid, cholesterol, and at least one triglyceride; and
an aqueous medium in which the dexamethasone encapsulated MVLs are suspended;
wherein the pH of the internal aqueous chambers of the MVLs is from about 6.5 to about 7.6;
wherein the dexamethasone or the ester or ester salt thereof is in the form of dexamethasone sodium phosphate,
wherein the concentration of dexamethasone sodium phosphate in the composition is from about 2 mg/mL to about 10 mg/mL, and
wherein the composition comprises less than 5% by weight of unencapsulated dexamethasone sodium phosphate of the total amount of dexamethasone sodium phosphate in the composition after storing at about 5° C. for at least 6 months.
2. The composition of claim 1 , wherein the pH of the internal aqueous chambers of the MVLs is about 7.5.
3. The composition of claim 1 , wherein the amphipathic lipid comprises a phosphatidylcholine or a salt thereof, a phosphatidylglycerol or a salt thereof, or combinations thereof.
4. The composition of claim 3 , wherein the phosphatidylglycerol is DPPG or a salt thereof.
5. The composition of claim 3 , wherein the phosphatidylcholine is selected from the group consisting of DEPC, DSPC, DMPC, DOPC, and salts and combinations thereof.
6. The composition of claim 1 , wherein the lipid membranes comprise DPPG, DEPC, cholesterol and at least one triglyceride.
7. The composition of claim 6 , wherein the triglyceride comprises triolein or tricaprylin, or a combination thereof, and wherein the percentage of the triglyceride in the lipid membrane is about 0.5% to about 30% by weight.
8. The composition of claim 1 , wherein the concentration of dexamethasone sodium phosphate in the composition is about 7 mg/mL.
9. The composition of claim 1 , wherein the aqueous medium in which the dexamethasone sodium phosphate encapsulated MVLs are suspended has a pH range from about 6.5 to about 7.5.
10. The composition of claim 9 , wherein the pH of the aqueous medium is about 7.0.
11. The composition of claim 1 , wherein the multivesicular liposomes have a D 50 particle size distribution from about 20 μm to about 40 μm.
12. The composition of claim 1 , wherein the percent packed particle volume (% PPV) of the dexamethasone sodium phosphate encapsulated MVLs in the composition is from about 20% to about 45%.
13. The composition of claim 1 , wherein a single administration of the composition provides a sustained release of dexamethasone sodium phosphate for about 14 days to about 28 days.
14. A method for treating or ameliorating pain or inflammation in a subject in need thereof, comprising administering a composition as in claim 1 to the subject.
15. The method of claim 14 , wherein the administration is selected from the group consisting of subcutaneous injection, tissue injection, intramuscular injection, spinal injection, intraarticular injection, intraocular injection, epidural injection, intrathecal injection, intraocular injection, intraotic injection, and perineural injection, and combinations thereof.
16. The method of claim 15 , wherein the administration is spinal injection, epidural injection, or intrathecal injection.
17. The method of claim 14 , wherein a single administration provides a sustained release of dexamethasone sodium phosphate for about 14 days to about 28 days.
18. The composition of claim 1 , wherein the pH modifying agent comprises phosphoric acid.
19. A composition of dexamethasone sodium phosphate encapsulated multivesicular liposomes (MVLs), comprising:
dexamethasone sodium phosphate and at least one pH modifying agent encapsulated in a plurality of internal aqueous chambers of the MVLs separated by lipid membranes,
wherein the lipid membranes comprise DEPC, DPPG, cholesterol, and at least one triglyceride,
wherein the triglyceride is selected from triolein and tricaprylin, or a combination thereof, and wherein the percentage of triglyceride in the lipid membrane is about 15% to about 30% by weight; and
an aqueous medium in which the dexamethasone sodium phosphate encapsulated MVLs are suspended;
wherein dexamethasone sodium phosphate encapsulated MVLs have an internal pH from about 6.5 to about 7.6,
the concentration of dexamethasone sodium phosphate in the composition is from about 3.5 mg/mL to about 8 mg/mL, and
the composition comprises less than 5% by weight of unencapsulated dexamethasone sodium phosphate of the total amount of dexamethasone sodium phosphate in the composition after storing at about 5° C. for at least 6 months.
20. The composition of claim 19 , wherein the dexamethasone sodium phosphate encapsulated MVLs have an internal pH from about 7.1 to about 7.6.
21. The composition of claim 20 , wherein the concentration of dexamethasone sodium phosphate in the composition is about 7 mg/mL.
22. A method for treating or ameliorating pain in a subject in need thereof, comprising administering a single epidural injection of the composition of claim 21 to the subject, wherein the administration provides a sustained release of dexamethasone sodium phosphate from about 14 days to about 28 days.